哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗78例老年社区获得性肺炎的疗效及安全性

Efficacy and safety of piperacillin sodium and tazobactam sodium combined with levofloxacin in the treatment of 78 cases of senile patients with community-acquired pneumonia

目的探讨哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗78例老年社区获得性肺炎(CAP)的疗效及安全性。方法选择2014年11月至2017年10月我院156例内科住院CAP老年患者,按照单盲法分为对照组和观察组,各78例。对照组予以哌拉西林钠他唑巴坦钠治疗,观察组联合左氧氟沙星治疗。疗程10 d,观察两组临床效果、不良反应及治疗前、后生活质量量表(SF-36)评分。结果治疗10 d后,观察组总有效率为92.31%,显著高于对照组78.21%(P<0.05);治疗10 d后,两组SF-36评分显著升高,且观察组明显高于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论老年性CAP患者予以哌拉西林钠他唑巴坦钠联合左氧氟沙星可显著提高疗效,生活质量明显改善,且安全性高。

Objective To investigate the efficacy and safety of piperacillin sodium and tazobactam sodium combinedwith levofloxacin in the treatment of 78 cases of senile community-acquired pneumonia （CAP）. Methods From November2014 to October 2017, 156 cases of elderly patients with CAP in the internal medicine department of our hospital wereselected and divided into control group and observation group according to single blind method, with 78 cases in eachgroup. The control group was treated with piperacillin sodium and tazobactam sodium, and the observation group wastreated with piperacillin sodium and tazobactam sodium combined with levofloxacin. Both groups were treated for 10 d,the clinical effects, adverse reactions and quality of life scale （SF-36） scores before and after treatment of both groupswere observed. Results After treatment of 10 d, the total effective rate of treatment in the observation group was 92.31%,which was higher than 78.21% of the control group （P〈0.05）. After treatment of 10 d, the SF-36 scores of the twogroups significantly improved, and that of the observation group was significantly higher than the control group （P〈0.05）.There was no significant difference in the total incidences of adverse reactions in the two groups （P〉0.05）. ConclusionThe piperacillin sodium and tazobactam sodium combined with levofloxacin in the treatment of elderly patients with CAPcan obviously improve the treatment effect and quality of life, with high safety.